Table 2.
Baseline characteristics of patients with T3N1M0 in the primary cohort B, cohort C, and PSM cohort
| Primary cohort | PSM cohort | |||||
|---|---|---|---|---|---|---|
| Cohort B: PET/CT + MRI (N = 1093) | Cohort C: MRI (N = 1377) | p | PET/CT + MRI (N = 954) | MRI (N = 954) | p | |
| N (%) | N (%) | N (%) | N (%) | |||
| Age | 0.021 | 0.911 | ||||
| Median(range) | 45 (12–79) | 47 (13–81) | 46 (12–79) | 46 (15–78) | ||
| < 55 | 867 (79.3) | 1037 (75.3) | 747 (78.3) | 750 (78.6) | ||
| ≥ 55 | 226 (20.7) | 340 (24.7) | 207 (21.7) | 204 (21.4) | ||
| Sex | 0.362 | 0.754 | ||||
| Male | 786 (71.9) | 966 (70.2) | 709 (74.3) | 702 (73.6) | ||
| Female | 307 (28.1) | 411 (29.8) | 245 (25.7) | 252 (26.4) | ||
| Albumin (g/L) | 0.014 | 0.445 | ||||
| < 40 | 51 (4.7) | 98 (7.1) | 48 (5.0) | 40 (4.2) | ||
| ≥ 40 | 1042 (95.3) | 1279 (92.9) | 906 (95.0) | 914 (95.8) | ||
| Hemoglobin (g/L) | 0.163 | 0.849 | ||||
| < 120 | 61 (5.6) | 97 (7.0) | 57 (6.0) | 60 (6.3) | ||
| ≥ 120 | 1032 (94.4) | 1280 (93.0) | 897 (94.0) | 894 (93.7) | ||
| LDH (U/L) | 0.949 | 0.904 | ||||
| < 250 | 1050 (96.1) | 1321 (95.9) | 919 (96.3) | 917 (96.1) | ||
| ≥ 250 | 43 (3.9) | 56 (4.1) | 35 (3.7) | 37 (3.9) | ||
| EBV DNA (copy/mL) | 0.721 | 1.000 | ||||
| < 4000 | 819 (74.9) | 1022 (74.2) | 712 (74.6) | 711 (74.5) | ||
| ≥ 4000 | 274 (25.1) | 355 (25.8) | 242 (25.4) | 243 (25.5) | ||
| Lymph node | < 0.001 | 0.882 | ||||
| Retropharyngeal lymph node | 299 (27.4) | 656 (47.6) | 295 (30.9) | 299 (31.3) | ||
| Cervical lymph node | 794 (72.6) | 721 (52.4) | 659 (69.1) | 655 (68.7) | ||
| Treatment | 0.162 | 0.578 | ||||
| CCRT | 489 (44.7) | 584 (42.4) | 407 (42.7) | 422 (44.2) | ||
| IC + CCRT | 349 (31.9) | 418 (30.4) | 311 (32.6) | 297 (31.1) | ||
| RT | 116 (10.6) | 163 (11.8) | 106 (11.1) | 93 (9.7) | ||
| IC + RT | 139 (12.7) | 212 (15.4) | 130 (13.6) | 142 (14.9) | ||
| Smoking | 0.266 | 0.610 | ||||
| Yes | 296 (27.1) | 402 (29.2) | 261 (27.4) | 272 (28.5) | ||
| No | 797 (72.9) | 975 (70.8) | 693 (72.6) | 682 (71.5) | ||
| Drinking | 0.387 | 0.749 | ||||
| Yes | 175 (16.0) | 202 (14.7) | 141 (14.8) | 147 (15.4) | ||
| No | 918 (84.0) | 1175 (85.3) | 813 (85.2) | 807 (84.6) | ||
| History | 1.000 | 0.323 | ||||
| Yes | 107 (9.8) | 135 (9.8) | 74 (7.8) | 87 (9.1) | ||
| No | 986 (90.2) | 1242 (90.2) | 880 (92.2) | 867 (90.9) | ||
Abbreviations: CCRT, concurrent chemoradiotherapy; EBV, Epstein-Barr virus; IC, induction chemotherapy; LDH, serum lactate dehydrogenase; MRI, magnetic resonance imaging; PSM, propensity scoring matching; PET/CT, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography; RT, radiotherapy